Based on the Cyclo Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Cyclo Therapeutics Inc is not available over the next 12 months. Cyclo Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cyclo Therapeutics Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Cyclo Therapeutics Inc’s stock price was USD 0.72. Cyclo Therapeutics Inc’s stock price has changed by +0.00% over the past week, +2.94% over the past month and -41.89% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Cyclo Therapeutics Inc
No recent average analyst rating found for Cyclo Therapeutics Inc
Company Overview Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Read Less
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, whic...Read More
Frequently Asked Questions About Cyclo Therapeutics Inc (CYTH) Stock
Stock Target Advisor's fundamental analysis for Cyclo Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on CYTH's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYTH's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CYTH's stock to indicate if its overvalued.
The last closing price of CYTH's stock was USD 0.72.
The most recent market capitalization for CYTH is USD 0.02B.
Unfortunately we do not have enough analyst data on CYTH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclo Therapeutics Inc's stock.
As per our most recent records Cyclo Therapeutics Inc has 8 Employees.
Cyclo Therapeutics Inc's registered address is 6714 NW 16th Street, Gainesville, FL, United States, 32653.
You can get more information about it from Cyclo Therapeutics Inc's website at https://cyclotherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Cyclo Therapeutics Inc (CYTH) Stock
Stock Target Advisor's fundamental analysis for Cyclo Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on CYTH's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYTH's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CYTH's stock to indicate if its overvalued.
The last closing price of CYTH's stock was USD 0.72.
The most recent market capitalization for CYTH is USD 0.02B.
Unfortunately we do not have enough analyst data on CYTH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclo Therapeutics Inc's stock.
As per our most recent records Cyclo Therapeutics Inc has 8 Employees.
Cyclo Therapeutics Inc's registered address is 6714 NW 16th Street, Gainesville, FL, United States, 32653.
You can get more information about it from Cyclo Therapeutics Inc's website at https://cyclotherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CYTH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
